Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome

Ruiz-Moreno, José M.; Montero, Javier A.; Gómez‐Ulla, Francisco; Ares, Sergio

doi:10.1136/bjo.2008.145391

Cited by 65 publications

(59 citation statements)

References 33 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are in accordance with those of other reports concerning ranibizumab [14,15,17,25,29,30] and bevacizumab [11,12,13,16] with shorter follow-up periods. Although most of these studies have used the logMAR scale for the assessment of BCVA, two distinct studies, using the ETDRS scale, reported a gain of 18.2 letters at 1 year [13] and 16.5 letters at 2 and 3 years [24] of treatment with IVB.…”

Section: Discussionsupporting

confidence: 83%

“…The short-term functional results have been positive with both intravitreal bevacizumab (IVB) and intravitreal ranibizumab (IVR), with a significant gain in best-corrected VA (BCVA) at 12 months in prospective [11,12,13,14,15] and retrospective [16,17] studies. Gharbiya et al [13] reported an improvement of 12.38 letters in mCNV eyes treated with IVB.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anti-VEGF Therapy in Myopic Choroidal Neovascularization: Long-Term Results

Freitas-da-Costa

Pinheiro-Costa²,

Carvalho³

et al. 2014

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To evaluate the medium- and long-term efficacy of anti-VEGF agents in the treatment of choroidal neovascularization secondary to pathologic myopia (mCNV). Methods: We performed a retrospective analysis of patients with mCNV who had been treated with intravitreous anti-VEGF for at least 2 years. The best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were compared before and after the treatment. The number of injections per year was also assessed. Results: The results were analysed at 2 years for 67 eyes, at 3 years for 52 eyes, at 4 years for 28 eyes and at 5 years for 13 eyes. The mean change from baseline BCVA was significant at 2 years (+8.6 letters; p < 0.001) and this gain remained significantly stable for a period of 5 years. The mean CRT showed a significant decrease over time, with a nadir at 2 years (-104.0 μm; p < 0.001). The mean number of injections performed during the first year was 5.2, being lower in subsequent years (p < 0.001). Conclusion: In this subset of patients with mCNV, an intravitreous therapy with anti-VEGF agents proved to have effective results over 5 years, with a sustained increase in BCVA.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Introductionmentioning

confidence: 99%

Anti-VEGF Therapy in Myopic Choroidal Neovascularization: Long-Term Results

Freitas-da-Costa

Pinheiro-Costa²,

Carvalho³

et al. 2014

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…[9][10][11][12][13][14][15][16][17][18][19][20][21][22] However, the follow-up periods were up to 1-year in most of the earlier studies. There have been a few studies that showed 2-years visual outcomes of IVB for mCNV, and the results have been conflicting.…”

Section: Discussionmentioning

confidence: 99%

“…6 Because of the poor natural history of mCNVs, several procedures have been tried to treat mCNVs, for example, thermal laser photocoagulation, 7 photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis Pharma AG, Basel, Switzerland), 8 and intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA, USA), a recombinant humanized monoclonal anti-VEGF antibody. Earlier case series have reported good visual outcomes 1 to 2 years after intravitreal bevacizumab (IVB), [9][10][11][12][13][14][15][16][17][18][19][20][21] and at present IVB would be the first-line therapy for sub-and juxtafoveal mCNVs. 22 However, there is still not enough information to predict the visual outcome of each patient with mCNV treated with IVB.…”

Section: Introductionmentioning

confidence: 99%

Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization

Nakanishi

Tsujikawa

Yodoi

et al. 2011

Eye

View full text Add to dashboard Cite

Purpose To determine the pre-treatment ocular factors significantly associated with the visual outcome 24 months after intravitreal bevacizumab (IVB) for myopic choroidal neovascularization (mCNV). Methods A total of 23 eyes of 23 patients with mCNV were treated with IVB followed by as needed therapy. The efficacy of IVB was evaluated by the best-corrected visual acuity (BCVA) at 24 months after the initial treatment. Forward stepwise multiple linear regression analyses were performed to evaluate the influence of pre-treatment factors on the BCVA and the improvement of the BCVA at 24 months. Results The mean pre-IVB BCVA was 0.74±0.30 logarithm of the minimum angle of resolution (logMAR) units, and it improved to 0.43±0.31 logMAR units after 1 month (Po0.001, paired t-test). The improvement was maintained at 24 months (0.46 ± 0.40, Po0.005). The mean number of IVB performed during the 24 months was 1.35 ± 0.71. Forward stepwise regression analysis showed that the pre-IVB CNV size (standardized b ¼ 0.52, Po0.01) and BCVA (standardized b ¼ À0.44, Po0.05) significantly affected the visual acuity change after 24 months. The CNV size was the only factor that significantly affected the BCVA after 24 months (standardized b ¼ 0.56, Po0.01). Conclusions IVB with as needed therapy for mCNV led to a rapid and sustained visual improvement. Smaller CNV size was a significant prognostic factor that predicts better visual acuity. Patients with lower pre-treatment BCVA had better visual recovery than those with better pre-treatment BCVA, however, this may be due to a ceiling/floor effect.

show abstract

“…However, none has achieved a beneficial long-term effect [4][5][6]. Intravitreal bevacizumab (IVB) (Avastin, Genentech, South San Francisco, CA) recently has been used widely and has achieved favorable visual outcomes [7][8][9][10][11][12][13]. A superior beneficial effect over that of other treatments also has been reported [14].…”

mentioning

confidence: 99%